Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7:585-98; PMID:17646864; http://dx.doi.org/10.1038/nrc2189
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20; PMID:15809451; http://dx.doi.org/10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Protti MP, Monte LD, Lullo GD. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens 2014; 83:237-46; PMID:24641502; http://dx.doi.org/10.1111/tan.12329
   PubMed Web of Science ®Google Scholar
• Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014; 25:257-71; PMID:24856143; http://dx.doi.org/10.1016/j.cytogfr.2014.04.005
   PubMed Web of Science ®Google Scholar
• Di Lullo G, Marcatti M, Heltai S, Brunetto E, Tresoldi C, Bondanza A, Bonini C, Ponzoni M, Tonon G, Ciceri F, et al. Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. Oncoimmunology 2015; 4:e1005460; PMID:26155400; http://dx.doi.org/10.1080/2162402X.2015.1005460
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857-63; PMID:19578369; http://dx.doi.org/10.1038/ni.1767
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009; 10:864-71; PMID:19578368; http://dx.doi.org/10.1038/ni.1770
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7; PMID:17676044; http://dx.doi.org/10.1038/ni1497
   PubMed Web of Science ®Google Scholar
• Akdis M, Palomares O, van de Veen W, van Splunter M, Akdis CA. TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. J Allergy Clin Immunol 2012; 129:1438-49; quiz50-1; PMID:22657405; http://dx.doi.org/10.1016/j.jaci.2012.05.003
   PubMed Web of Science ®Google Scholar
• Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 2015; 33:747-85; PMID:25706098; http://dx.doi.org/10.1146/annurev-immunol-032414-112123
   PubMed Web of Science ®Google Scholar
• Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 2010; 22:821-6; PMID:21087848; http://dx.doi.org/10.1016/j.coi.2010.10.013
   PubMed Web of Science ®Google Scholar
• Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R, Gaston H. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013; 15:R136; PMID:24286492; http://dx.doi.org/10.1186/ar4317
   PubMed Web of Science ®Google Scholar
• Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: the ultimate identity crisis. Front Immunol 2014; 5:276; PMID:24987392; http://dx.doi.org/10.3389/fimmu.2014.00276
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115:5385-92; PMID:20395418; http://dx.doi.org/10.1182/blood-2009-10-246660
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S, Dhodapkar MV. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112:2878-85; PMID:18669891; http://dx.doi.org/10.1182/blood-2008-03-143222
   PubMed Web of Science ®Google Scholar
• Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116:3554-63; PMID:20664052; http://dx.doi.org/10.1182/blood-2010-05-283895
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203:2673-82; PMID:17088434; http://dx.doi.org/10.1084/jem.20061775
   PubMed Web of Science ®Google Scholar
• Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007; 204:2803-12; PMID:18025126; http://dx.doi.org/10.1084/jem.20071397
   PubMed Web of Science ®Google Scholar
• Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, et al. CC-chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008; 68:6840-50; PMID:18703490; http://dx.doi.org/10.1158/0008-5472.CAN-08-0402
   PubMed Web of Science ®Google Scholar
• Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006; 108:3992-6; PMID:16917004; http://dx.doi.org/10.1182/blood-2006-05-026112
   PubMed Web of Science ®Google Scholar
• Galson DL, Silbermann R, Roodman GD. Mechanisms of multiple myeloma bone disease. Bonekey Rep 2012; 1:135; PMID:23951515; http://dx.doi.org/10.1038/bonekey.2012.135
   PubMedGoogle Scholar
• Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7:292-304; PMID:17380158; http://dx.doi.org/10.1038/nri2062
   PubMed Web of Science ®Google Scholar
• Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, Silvestris F. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. Br J Haematol 2013; 161:821-31; PMID:23594390; http://dx.doi.org/10.1111/bjh.12333
   PubMed Web of Science ®Google Scholar
• Sun Y, Pan J, Mao S, Jin J. IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression. PLoS One 2014; 9:e114647; PMID:25489847; http://dx.doi.org/10.1371/journal.pone.0114647
   PubMedGoogle Scholar
• Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, Fromm P, Gibson J, Khoo L, Ho PJ, et al. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma 2014; 55:1090-8; PMID:23865833; http://dx.doi.org/10.3109/10428194.2013.825905
   PubMed Web of Science ®Google Scholar
• Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012; 2012:293479; PMID:22489248; http://dx.doi.org/10.1155/2012/293479
   PubMed Web of Science ®Google Scholar
• Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013; 3:e148; PMID:24036947; http://dx.doi.org/10.1038/bcj.2013.34
   PubMed Web of Science ®Google Scholar
• Tsirakis G, Pappa CA, Kolovou A, Kokonozaki M, Neonakis I, Alexandrakis MG. Clinical significance of interleukin-22 in multiple myeloma. Hematology 2015; 20:143-7; PMID:25055724; http://dx.doi.org/10.1179/1607845414Y.0000000182
   PubMed Web of Science ®Google Scholar
• Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101:2129-39; PMID:9593769; http://dx.doi.org/10.1172/JCI741
   PubMed Web of Science ®Google Scholar